Antitumor activity of fucoidan in anaplastic thyroid cancer via apoptosis and anti-angiogenesis

Shen,Hong‑Yan; Li,Lan‑Zhen; Xue,Ke‑Cheng; Hu,Dan‑Dan; Gao,Yu‑Jun

doi:10.3892/mmr.2017.6338

Antitumor activity of fucoidan in anaplastic thyroid cancer via apoptosis and anti-angiogenesis

Authors:
- Hong‑Yan Shen
- Lan‑Zhen Li
- Ke‑Cheng Xue
- Dan‑Dan Hu
- Yu‑Jun Gao
View Affiliations

Affiliations: Department of Thyroid and Breast Surgery, Linyi People's Hospital, Linyi, Shandong 276003, P.R. China, Department of Surgery, People's Hospital of Linzi District Affiliated to Binzhou Medical College, Zibo, Shandong 255400, P.R. China
Published online on: March 16, 2017 https://doi.org/10.3892/mmr.2017.6338
Pages: 2620-2624

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study demonstrated the effect of fucoidan, isolated from Fucus vesiculosus, on cell growth and apoptosis in anaplastic thyroid cancer cells. The cell viability was analyzed using a Cell Counting Kit‑8 cell proliferation kit. Diamidino-2-phenylindole and terminal deoxynucleotidyl transferase-mediated dUTP nick‑end labeling assays were used to examine the apoptotic effect of fucoidan, which revealed the presence of apoptotic bodies and DNA fragmentation. Fucoidan inhibited the growth of FTC133 and TPC1 ATC cells in a dose‑dependent manner. It also induced the apoptosis of FTC133 cells by promoting the expression levels of cleaved poly ADP‑ribose polymerase and caspase‑3. Significant decreases in the levels expression of hypoxia-inducible factor 1α and vascular endothelial growth factor were observed in the FTC133 cells following treatment of the cells with fucoidan. In addition, inhibition in tube formation and the migration of FTC133 cells were observed in the cells treated with fucoidan, compared with the cells in the control group. Therefore, fucoidan inhibited cell growth, induced apoptosis and suppressed angiogenesis in the thyroid cancer cells.

View Figures

View References

1	American Cancer Society: Cancer Facts and Figures. American Cancer Society; Atlanta, GA: pp. 30303–1002. 2009
2	Catalano MG, Poli R, Pugliese M, Fortunati N and Boccuzzi G: Emerging molecular therapies of advanced thyroid cancer. Mol Aspects Med. 31:215–226. 2010. View Article : Google Scholar : PubMed/NCBI
3	Fassnacht M, Kreissl MC, Weismann D and Allolio B: New targets and therapeutic approaches for endocrine malignancies. Pharmacol Ther. 123:117–141. 2009. View Article : Google Scholar : PubMed/NCBI
4	Patel KN and Shaha AR: Poorly differentiated and anaplastic thyroid cancer. Cancer Control. 13:119–128. 2006.PubMed/NCBI
5	Sakorafas GH, Sampanis D and Safioleas M: Cervical lymph node dissection in papillary thyroid cancer: Current trends, persisting controversies, and unclarified uncertainties. Surg Oncol. 19:e57–e70. 2010. View Article : Google Scholar : PubMed/NCBI
6	Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH and DeConti R: A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 56:2155–2160. 1985. View Article : Google Scholar : PubMed/NCBI
7	Ahuja S and Ernst H: Chemotherapy of thyroid carcinoma. J Endocrinol Invest. 10:303–310. 1987. View Article : Google Scholar : PubMed/NCBI
8	Fleming ID, Phillips JL, Menck HR, Murphy GP and Winchester DP: The national cancer data base report on recent hospital cancer program progress toward complete American joint committee on cancer/TNM staging. Cancer. 80:2305–2310. 1997. View Article : Google Scholar : PubMed/NCBI
9	Gilliland FD, Hunt WC, Morris DM and Key CR: Prognostic factors for thyroid carcinoma. A population-based study of 15, 698 cases from the surveillance, epidemiology and end results (SEER) program 1973–1991. Cancer. 79:564–573. 1997. View Article : Google Scholar : PubMed/NCBI
10	Hundahl SA, Fleming ID, Fremgen AM and Menck HR: A National Cancer Data Base report on 53, 856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments]. Cancer. 83:2638–2648. 1998. View Article : Google Scholar : PubMed/NCBI
11	Ain KB: Anaplastic thyroid carcinoma: Behavior, biology, and therapeutic approaches. Thyroid. 8:715–726. 1998. View Article : Google Scholar : PubMed/NCBI
12	Are C and Shaha AR: Anaplastic thyroid carcinoma: Biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol. 13:453–464. 2006. View Article : Google Scholar : PubMed/NCBI
13	Jereb B, Stjernswärd J and Löwhagen T: Anaplastic giant cell carcinoma of the thyroid. A study of treatment and prognosis. Cancer. 35:1293–1295. 1975. View Article : Google Scholar : PubMed/NCBI
14	Junor EJ, Paul J and Reed NS: Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol. 18:83–88. 1992.PubMed/NCBI
15	Tan RK, Finley RK III, Driscoll D, Bakamjian V, Hicks WL Jr and Shedd DP: Anaplastic carcinoma of the thyroid: A 24-year experience. Head Neck. 17:41–47; discussion 47–48. 1995. View Article : Google Scholar : PubMed/NCBI
16	Tallroth E, Wallin G, Lundell G, Löwhagen T and Einhorn J: Multimodality treatment in anaplastic giant cell thyroid carcinoma. Cancer. 60:1428–1431. 1987. View Article : Google Scholar : PubMed/NCBI
17	Moro CO and Basile G: Obesity and medicinal plants. Fitoterapia. 71:(Suppl 1). S73–S82. 2000. View Article : Google Scholar : PubMed/NCBI
18	Saha M, Rempt M, Grosser K, Pohnert G and Weinberger F: Surface-associated fucoxanthin mediates settlement of bacterial epiphytes on the rockweed Fucus vesiculosus. Biofouling. 27:423–433. 2011. View Article : Google Scholar : PubMed/NCBI
19	Kwak KW, Cho KS, Hahn OJ, Lee KH, Lee BY, Ko JJ and Chung KH: Biological effects of fucoidan isolated from Fucus vesiculosus on thrombosis and vascular cells. Korean J Hematol. 45:51–57. 2010. View Article : Google Scholar : PubMed/NCBI
20	Parys S, Kehraus S, Krick A, Glombitza KW, Carmeli S, Klimo K, Gerhäuser C and König GM: In vitro chemopreventive potential of fucophlorethols from the brown alga Fucus vesiculosus L. by anti-oxidant activity and inhibition of selected cytochrome P450 enzymes. Phytochemistry. 71:221–229. 2010. View Article : Google Scholar : PubMed/NCBI
21	Řezanka T, Vyhnálek O and Podojil M: Separation and identification of lipids and fatty acids of the marine alga Fucus vesiculosus by TLC and GC-MS. Folia Microbiologica. 33:309–313. 1988. View Article : Google Scholar
22	Morris CA, Nicolaus B, Sampson V, Harwood JL and Kille P: Identification and characterization of a recombinant metallothionein protein from a marine alga Fucus vesiculosus. Biochem J. 338:553–560. 1999. View Article : Google Scholar : PubMed/NCBI
23	Yin F, Giuliano AE and Van Herle AJ: Growth inhibitory effects of flavonoids in human thyroid cancer cell lines. Thyroid. 9:369–376. 1999. View Article : Google Scholar : PubMed/NCBI
24	Cragg GM, Newman DJ and Yang SS: Natural product extracts of plant and marine origin having antileukemia potential. The NCI experience. J Nat Prod. 69:488–498. 2006. View Article : Google Scholar : PubMed/NCBI
25	O'Connor L, Huang DC, O'Reilly LA and Strasser A: Apoptosis and cell division. Curr Opin Cell Biol. 12:257–263. 2000. View Article : Google Scholar : PubMed/NCBI
26	Riedl SJ and Shi Y: Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol. 5:897–907. 2004. View Article : Google Scholar : PubMed/NCBI
27	Krishnakumar R and Kraus WL: The PARP side of the nucleus: Molecular actions, physiological outcomes, and clinical targets. Mol Cell. 39:8–24. 2010. View Article : Google Scholar : PubMed/NCBI
28	Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4–6. 1990. View Article : Google Scholar : PubMed/NCBI
29	Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI